Jiangsu Hengsheng Pharmaceutical Co., Ltd., located in the Economic Development Zone of Rugao City, Nantong City, Jiangsu Province, is a national high-tech enterprise and a Ministry of Industry and Information Technology (MIIT)-designated “Specialized, Refined, Distinctive, and Innovative” (SRDI) “Little Giant” enterprise, primarily engaged in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company has a registered capital of RMB 120 million, fully paid-in, was established in 2001, and first obtained national high-tech enterprise certification in 2015, which remains valid continuously through 2025.  

The company focuses on process development and large-scale manufacturing of high-end generic APIs targeting cardiovascular/cerebrovascular diseases, central nervous system disorders, and oncology. Its primary customers include leading domestic formulation enterprises and global generic drug clients. Its product portfolio includes APIs and key intermediates such as atorvastatin calcium, rosuvastatin calcium, and duloxetine hydrochloride.  

The company operates the Jiangsu Provincial Enterprise Technology Center, the Chiral Drug Engineering Technology Research Center, and a postdoctoral research workstation. It holds 32 Chinese-authorized invention patents and 9 PCT international patent applications; its core patents cover chiral synthesis, polymorph control, and green catalytic processes. Technologies applied in industrialization include enzymatic catalysis and continuous-flow microreactor systems, achieving solvent recovery rates exceeding 92% and energy consumption per unit 18% lower than the industry average.  

The company holds a Drug Manufacturing License (Su 20160001), is certified under ISO 9001/14001/45001 integrated management systems, and has obtained five European Union Certificates of a Suitability of the Active Substance for Use in Human Medicinal Products (CEPs), including Rosuvastatin Calcium CEP (2021-325-Rev01) and Atorvastatin Calcium CEP (2023-072-Rev02). It has passed U.S. FDA on-site inspections (Inspection ID: 525295) and audits by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and completed registration and filing with India’s Drugs Controller General of India (DCGI) in 2024.  

Representative achievements include stable supply of atorvastatin calcium to domestic formulation enterprises for over 10 years, with cumulative deliveries exceeding 300 metric tons; since 2022, serving as the designated API supplier for one of the world’s top three rosuvastatin formulation manufacturers, supplying markets across 12 countries including Germany, Brazil, and South Africa; and signing a five-year long-term supply agreement for rosuvastatin calcium with India’s Sun Pharma in 2025.  

Through its international business offices in Shanghai and Shenzhen, the company serves clients across more than 30 countries in Asia-Pacific, Latin America, and Africa. In 2025, its API export revenue amounted to RMB 187 million, accounting for 63% of total revenue. Publicly available information does not indicate involvement in EPC (Engineering, Procurement, and Construction) general contracting or complete equipment manufacturing businesses, nor does it disclose participation in national-level major new drug innovation programs or leadership in formulating national or industry standards.